NEW YORK (GenomeWeb News) - Illumina shares were down more than 8 percent in mid-morning trade today following a report from a German newspaper in which a Roche official said that an acquisition of the San Diego-based company is "off the table."

At press time, Illumina shares were trading at $49.77, down from their Friday close of $54.76.

Roche Chairman Franz Humer said in an interview with Germany's SonntagsZeitung that the company has no plans to acquire Illumina, which he characterized as a "nice to have" but not a "must have."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

Jun
12
Sponsored by
Philips Genomics

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.